Drug Patents owned by Astellas

1. List of Cresemba drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6812238 ASTELLAS N-substituted carbamoyloxyalkyl-azolium derivatives
Oct, 2025

(2 years from now)

US10812238 ASTELLAS Configurable reference signals
Oct, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10603280 ASTELLAS Active ingredient containing stabilised solid medicinal forms and methods for the production thereof
Sep, 2027

(4 years from now)

US10206879 ASTELLAS Active ingredient containing stabilised solid forms and method for the production thereof
Sep, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 6, 2020
Orphan Drug Exclusivity (ODE) Mar 6, 2022
Generating Antibiotic Incentives Now (GAIN) Mar 6, 2027

Drugs and Companies using ISAVUCONAZONIUM SULFATE ingredient

NCE-1 date: March, 2026

Market Authorisation Date: 06 March, 2015

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

2. List of Lexiscan drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6403567 ASTELLAS N-pyrazole A2A adenosine receptor agonists
Apr, 2022

(9 months ago)

US8106183 ASTELLAS Process for preparing an A2A-adenosine receptor agonist and its polymorphs
Feb, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE47301 ASTELLAS Process for preparing an A2A-adenosine receptor agonist and its polymorphs
Feb, 2027

(4 years from now)

Drugs and Companies using REGADENOSON ingredient

Market Authorisation Date: 10 April, 2008

Treatment: Method for stimulating coronary vasodilation for purposes of imaging the heart

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of LEXISCAN before it's patent expiration?
More Information on Dosage

3. List of Vesicare Ls drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9918970 ASTELLAS Pharmaceutical composition comprising solifenacin
May, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) May 26, 2023
Pediatric Exclusivity (PED) Nov 26, 2023

Drugs and Companies using SOLIFENACIN SUCCINATE ingredient

Market Authorisation Date: 26 May, 2020

Treatment: NA

Dosage: SUSPENSION;ORAL

How can I launch a generic of VESICARE LS before it's patent expiration?
More Information on Dosage

4. List of Xospata drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8969336 ASTELLAS Diamino heterocyclic carboxamide compound
Jan, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9487491 ASTELLAS Diamino heterocyclic carboxamide compound
Jul, 2030

(7 years from now)

US10786500 ASTELLAS Stable pharmaceutical composition for oral administration
Jul, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 28, 2025
New Chemical Entity Exclusivity (NCE) Nov 28, 2023

Drugs and Companies using GILTERITINIB FUMARATE ingredient

NCE-1 date: November, 2022

Market Authorisation Date: 28 November, 2018

Treatment: Treatment of acute myeloid leukemia (aml)

Dosage: TABLET;ORAL

More Information on Dosage

5. List of Xtandi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7709517 ASTELLAS Diarylhydantoin compounds
Aug, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9126941 ASTELLAS Treatment of hyperproliferative disorders with diarylhydantoin compounds
May, 2026

(3 years from now)

US8183274 ASTELLAS Treatment of hyperproliferative disorders with diarylhydantoin compounds
Aug, 2026

(3 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Dec 16, 2022

Drugs and Companies using ENZALUTAMIDE ingredient

Market Authorisation Date: 31 August, 2012

Treatment: The treatment of patients with metastatic castration-sensitive prostate cancer; Treatment of patients with castration-resistant prostate cancer (crpc)

Dosage: CAPSULE;ORAL

How can I launch a generic of XTANDI before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in